摘要
目的分析应用齐拉西酮治疗精神分裂症的总体疗效以及安全性,为精神分裂症临床用药加以指导。方法回顾分析120例精神分裂症患者的临床资料,随机分为实验组(齐垃西酮)和对照组(氟哌啶醇)两组,比较两组精神分裂症患者的疗效、不良反应等。结果实验组精神分裂症患者各项临床观察指标均优于对照组,经统计学分析,组间差异具有显著性(P<0.05)。结论对于精神分裂症患者来说,实施齐拉西酮疗效显著,且不良反应少,具有推广应用价值。
Objective To analyze the overall effect of ziprasidone in the treatment of schizophrenia as well as safety,schizophrenia clinical medication guidance.Methods A retrospective analysis of the clinical data of 120 patients with schizophrenia,were randomly divided into experimental group(Qi La West ketone)and control group(haloperidol)two group,compared two groups of patients with schizophrenia eff icacy,adverse reactions. Results The experimental group spirit of the patients clinical observation indexes were better than the control group division,through statistical analysis, the difference between groups was signif icant(P <0.05).Conclusion For patients with schizoph renia,the implementation of ziprasidone has obvious curative effect,and less adverse reaction,and has popularization and application value.
出处
《中国卫生产业》
2013年第32期143-143,145,共2页
China Health Industry
作者简介
苏理成（1959-）,男,专科,主治医师,从事精神科临床31年.
